News @ a glance
- Indicators of political commitment to respond to HIV. Goldberg, Allison B.; Fox, Ashley M.; Gore, Radhika J.; Bärnighausen, Till // Sexually Transmitted Infections;Mar2012, Vol. 88 Issue 2, p1
Objectives National political commitment is likely to become particularly crucial to sustaining antiretroviral treatment programmes in the coming decade, as donor contributions to HIV funding decreases. The objective of this study is to synthesise information on existing indicators of political...
- Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment. Nunn, Amy S.; Fonseca, Elize M.; Bastos, Francisco I.; Gruskin, Sofia; Salomon, Joshua A. // PLoS Medicine;Nov2007, Vol. 4 Issue 11, pe305
Amy Nunn and colleagues analyze the cost of antiretroviral drugs in Brazil between 2001 and 2005 and discuss the implications for HIV treatment in other developing countries.
- The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa -- a primary data analysis. Cleary, Susan M.; McIntyre, Di; Boulle, Andrew M. // Cost Effectiveness & Resource Allocation;2006, Vol. 4, p20
Background: Given the size of the HIV epidemic in South Africa and other developing countries, scaling up antiretroviral treatment (ART) represents one of the key public health challenges of the next decade. Appropriate priority setting and budgeting can be assisted by economic data on the costs...
- The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. Rosen, Sydney; Long, Lawrence; Sanne, Ian; Stevens, Wendy S.; Fox, Matthew P. // Journal of the International AIDS Society;2011, Vol. 14 Issue 1, p1
Background: Current guidelines for providing antiretroviral therapy (ART) in South Africa's public sector programme call for switching patients from first-line to second-line treatment upon virologic failure as indicated by two consecutive viral loads above 5000 copies/ml, but without laboratory...
- Adapting a community-based ART delivery model to the patients' needs: a mixed methods research in Tete, Mozambique. Rasschaert, Freya; Decroo, Tom; Remartinez, Daniel; Telfer, Barbara; Lessitala, Faustino; Biot, Marc; Candrinho, Baltazar; Van Damme, Wim // BMC Public Health;2014, Vol. 14 Issue 1, p1
Background To improve retention in antiretroviral therapy (ART), lessons learned from chronic disease care were applied to HIV care, providing more responsibilities to patients in the care of their chronic disease. In Tete - Mozambique, patients stable on ART participate in the ART provision and...
- First medication in new class of ARTs poised to be available for salvage therapy. // AIDS Alert;Aug2007, Vol. 22 Issue 8, p85
The article reports on the expected approval of Maraviroc, a CCR5 antagonist to be marketed by Pfizer under the trade name of Celsentri, by the U.S. Food and Drug Administration in July or August 2007.
- Current Treatment of HIV Infection. Portsmouth, Simon; Stebbing, Justin; Gazzard, Brian // Current Topics in Medicinal Chemistry;Sep2003, Vol. 3 Issue 13, p1458
The field of antiretroviral therapy has witnessed remarkable progress during the past 15 years. There are now over a dozen approved therapeutic agents for infection with the human immunodeficiency virus (HIV), a pathogen that once caused nearly uniformly fatal illness. These agents usually...
- Lamivudine/Zidovudine/Abacavir. Ibbotson, Tim; Perry, Caroline M. // Drugs;2003, Vol. 63 Issue 11, p1089
â€¢ The triple combination tablet containing lamivudine (150mg), zidovudine (300mg) and abacavir (300mg, as abacavir sulfate) is a new formulation of three nucleoside analogue reverse transcriptase inhibitors. â€¢ Two studies in treatment-naive patients (one double-blind, one nonblind)...
- Lamivudine/Zidovudine/Abacavir A Viwepoint by David Haas. Haas, David // Drugs;2003, Vol. 63 Issue 11, p1099
Comments on the triple combination tablet containing antiretrovirals lamivudine, zidovudine and abacavir for the treatment of HIV infection. Factors that influence decisions regarding when to initiate antiretroviral therapy; Antiviral potency; Adverse effects.